Efficacy of Formulated Posterior Subtenon Triamcinolone in Macular Edema secondary to Non–Ischemic Retinal Vein Occlusions | ||||
| International Journal of Medical Arts | ||||
| Article 7, Volume 4, Issue 6, June 2022, Page 2440-2447 PDF (1.04 MB) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ijma.2022.149628.1482 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Ehab Tharwat   1; Akram Fekry Elgazar1; Riad Elzaher Hassan Ahmed2
| ||||
| 1Department of Ophthalmology, Damietta Faculty of Medicine, Al-Azhar University, Damietta, Egypt. | ||||
| 2Department of Ophthalmology, Faculty of Medicine, Al-Azhar University, Damietta, Egypt. | ||||
| Abstract | ||||
| Background: Retinal vein occlusion [RVO] is considered the second vascular disorder of the retina after diabetic retinopathy. Patients with RVO are at risk of the development of macular edema, which may be treated by triamcinolone. The Aim of the work: To detect the efficacy of formulated Triamcinolone Acetonide [TA] injection in the posterior subtenon space to manage macular edema secondary to non-ischemic RVOs, either central or branch. Patients and methods: Our study included forty-six eyes from 46 patients with non-ischemic RVO. All the eyes received a single dose of 40 mg of Triamcinolone Acetonide [TA] and VISCOAT, which is 20 mg sodium chondroitin sulfate and 15 mg sodium hyaluronate [0.5 ml] through the posterior subtenon route using NAGATA subtenon canula. Complete ophthalmic examinations were done at the baseline and after one, three, and six months of injections. Result: The mean age of patients was 58.28±5.19 years. BCVA increased from 0.40 [0.10-0.70] at baseline to 0.75 [0.10-1.00] at the 1st ,3rd and 6th month [P < 0.001]. The median baseline OCT thickness changed from 411.50 [294.00-624.00] μm pre-injection to 265.00[187.00-614.00] μm [1st month], 265.00 [187.00-614.00] μm [3rd month], and 209.00 [178.00-531.00] m [6th month] [p<0.001]. The median IOP decreased from 13.00 [11.00-18.00] mm Hg on initial assessment to 12.00 [10.00-16.00] at the end of the study without any elevation at any point. Conclusion: Formulated posterior subtenon triamcinolone acetonide [PSTA] is an effective treatment for macular edema secondary to Non- Ischemic RVO with minimal complications. | ||||
| Keywords | ||||
| Retinal vein occlusion; Posterior Subtenon; Triamcinolone; Macular edema | ||||
|
Statistics Article View: 256 PDF Download: 156 |
||||
